络泰联合低分子肝素治疗急性肺栓塞的临床研究

目的评价络泰联合低分子肝素治疗急性肺栓塞的疗效。方法将确诊的102例急性肺栓塞患者分为2组,A组患者(n=55)单用低分子肝素4100IU,皮下注射,每日2次,共12天。B组患者(n=57)在A组的治疗方案的基础上,加用络泰粉剂0.8g,溶于生理盐水200m l静脉滴注,1小时滴完,每日1次。对比观察疗效。结果2组患者治疗后的各项临床和实验指标均有明显改善,A组治疗有效率为69.1%,B组为75.4%,B组的有效率明显高于A组,差异有统计学意义。鼻出血和皮下出血并发症两组无差异。结论络泰联合低分子肝素治疗急性肺栓塞是安全、有效的。

Clinical study of the efficacy of therapy with luotai with low molecular weight heparin in acute pulmonary embolism

Objective To evaluate the efficacy of therapy with luotai with low molecular weight heparin in acute pulmonary embolism.Methods We conducted a randomized,case control trial.102 patients with acute pulmonary embolism were randomly divided into 2 groups: Group A(n=55) were treated with lower molecular weight heparin alone and Group B(n=57) were treated with luotai with low molecular weight heparin.Results For both groups,the clinical and experimental indexes were improved.The effective rate of low molecular weight heparin therapy and luotai with low molecular weight heparin were 69.1% and 75.4%,respectively,for Group A and Group B,and the effective rate of Group B was significantly better than Group A.There was no group difference in nasal hemorrhage and subcutaneous hemorrhage.Conclusion The therapy with luotai with low molecular weight is effective and safe in treating acute pulmonary embolism.